Brief: PharmaCyte Biotech Expands Product Pipeline To Include Diabetes And Malignant Ascites Following $90-Million Capital Raise
25/08/2021 14:19
Aug 25 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH EXPANDS PRODUCT PIPELINE TO INCLUDE
DIABETES
AND MALIGNANT ASCITES FOLLOWING $90-MILLION CAPITAL RAISE
Source text for Eikon: ID:nBw91mJ0ta
Further company coverage: PMCB.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer